Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Visits to emergency rooms in Indiana for drug overdoses are falling, and doctors are writing fewer prescriptions for opioid painkillers, Jim McClelland said Friday.
Eli Lilly and Co. received clearance Thursday from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
The Indianapolis medical-software firm recently raised $10 million in venture funding and is launching two major products in one month.
Overdose deaths in Indiana rose 18 percent last year compared with 2016 and 37 percent over 2015. A vast majority of the overdoses were caused by opioids.
A boom in major U.S. pharmaceutical stocks is creating a swarm of activity around an exchange-traded fund tracking major drugmakers like Eli Lilly and Co.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
New therapies that could cure diseases caused by defective genes will get quicker approval from U.S. regulators, part of an effort by the Food and Drug Administration to keep pace with one of biotechnology’s fastest-growing fields.
President Donald Trump’s interest in the bill stems from a push by Vice President Mike Pence, who championed the initiative when he was governor of Indiana.
Brian Griffin, the leader of Anthem’s new PBM, IngenioRx, quit on May 8 with no warning to become CEO of Michigan-based Diplomat Pharmacy. Now Anthem is scrambling to adjust.
President Donald Trump's long-awaited plan to bring down drug prices, unveiled Friday, will mostly spare the pharmaceutical industry he previously accused of "getting away with murder" and instead focus on increasing private competition.
President Donald Trump is set to unveil his long-awaited plan for reducing drug prices after more than a year of bold promises to tackle pharmacy costs that are squeezing millions of Americans.
The newly built farm uses a high-fat, high-cholesterol diet to give animals heart disease and diabetes to help medical researchers find treatments.
The drug industry set several quarterly records for lobbying spending in the first three months of 2018, but Indianapolis-based Eli Lilly and Co. actually reduced lobbying expenditures.
